The promise and perils of 'targeted therapy' of advanced ovarian cancer

Oncology

Volumn 74, Issue 1-2, 2008, Pages 1-6

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti angiogenic agents; Bevacizumab; Epidermal growth factor inhibitors; Ovarian cancer; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MATUZUMAB; PACLITAXEL; PERTUZUMAB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE;

CANCER CHEMOTHERAPY; CANCER THERAPY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 46249097421     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000138349     Document Type: Review

References (52)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Covens A, Carey M, Bryson P, Verma S, Fung Kee FM, Johnston M: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002;85:71-80.
3. Cannistra SA: Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
4. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
5. Markman M: Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer? Gynecol Oncol 2001;83:449-450.
6. Markman M: Viewing ovarian cancer as a 'chronic disease': what exactly does this mean? Gynecol Oncol 2006;100:229-230.
7. Markman M, Bookman MA: Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
8. Bergman F: Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966;45:211-231.
9. Vergote I, Rustin GJ, Eisenhauer EA, et al: Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000;92:1534-1535.
10. Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M: An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007;25:3615-3620.
11. Markman M, Markman J, Webster K, et al: Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120-3125.
12. Harrison ML, Gore ME, Spriggs D, et al: Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol 2007;106:469-475.
13. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
14. Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
15. Felip E, del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B: Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995;75:2147-2152.
16. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W: Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998;17:61-65.
17. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-290.
18. Gordon MS, Matei D, Aghajanian C, et al: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with HER2 activation status. J Clin Oncol 2006;24:4324-4332.
19. Makhija S, Glenn D, Ueland F, et al: Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2007;25(18s):275s. Abstract 5507.
20. Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T: The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989;9:1537-1547.
21. Berchuck A, Rodriguez GC, Kamel A, et al: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-674.
22. Wagner U, du Bois A, Pfisterer J, et al: Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-137.
23. Seiden MV, Burris HA, Matulonis U, et al: A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007;104:727-731.
24. Schilder RJ, Sill MW, Chen X, et al: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11:5539-5548.
25. Posadas EM, Liel MS, Kwitkowski V, et al: A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109:1323-1330.
26. Gordon AN, Fickler N, Edwards RP, et al: Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005;15:785-792.
27. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
28. Paez JG, Panne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
29. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
30. Goldman JM, Melo JV: Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1084-1086.
31. Demetri GD, von MM, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
32. Schmandt RE, Broaddus R, Lu KH, et al: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003;98:758-764.
33. Apte SM, Fan D, Killion JJ, Fidler IJ: Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004;10:897-908.
34. Matei D, Chang DD, Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004;10:681-690.
35. Coleman RL, Broaddus RR, Bodurka DC, et al: Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101:126-131.
36. Alberts DS, Liu PY, Wilczynski SP, et al: Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007, in press.
37. Burger RA, Sill M, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2005;23(suppl 1):457s.
38. Cannistra SA, Matulonis U, Person R, et al: Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 2006;34(18S):257s.
39. Garcia AA, Oza AM, Hirte H, et al: Interim report of a phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian and primary peritoneal carcinoma: a California Cancer Consortium Trial. J Clin Oncol 2005;23(suppl 1):455s.
40. Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006;107:83-89.
41. Monk BJ, Choi DC, Pugmire G, et al: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96:902-905.
42. Numnum TM, Rocconi RP, Whitworth J, et al: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006;102:425-428.
43. Chura JC, Iseghem KV, Downs LS Jr, et al: Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007;107:326-330.
44. Simpkins F, Belinson JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007;107:118-123.
45. Cohn DE, Valmadre S, Resnick KE, et al: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006;102:134-139.
46. Aghajanian C: The role of bevacizumab in ovarian cancer - an evolving story. Gynecol Oncol 2006;102:131-133.
47. Frumovitz M, Sood AK: Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 2007;104:768-778.
48. Cilley JC, Barfi K, Benson AB III, et al: Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2007;7:739-749.
49. Tew WP, Colombo N, Ray-Coquard I, et al: VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized multi-center phase II study. J Clin Oncol 2007;25(18S):276s.
50. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465.
51. Markman M, Liu P, Wilcyznski S, et al: Survival of ovarian cancer patients treated on SWOG 9701/GOG178:12 versus 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum/paclitaxel. J Clin Oncol 2006;24(18S):257s.
52. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943.